Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Alligator Bioscience AB ( (SE:ATORX) ) has provided an announcement.
Alligator Bioscience announced that the European Commission has granted orphan drug designation to HLX22, an anti-HER2 monoclonal antibody, for treating gastric cancer. This designation, following a similar one from the U.S. FDA, underscores HLX22’s potential in treating HER2-positive gastric cancer and could contribute future revenue to Alligator through its licensing agreement with AbClon and Henlius.
More about Alligator Bioscience AB
Alligator Bioscience is a clinical-stage biotechnology company based in Lund, Sweden, specializing in the development of tumor-directed immuno-oncology antibody drugs. The company focuses on the CD40 receptor to enhance the immune system’s response against cancer, with its lead drug candidate, mitazalimab, advancing towards Phase 3 development.
YTD Price Performance: -81.14%
Average Trading Volume: 244,328
Current Market Cap: SEK67.13M
For a thorough assessment of ATORX stock, go to TipRanks’ Stock Analysis page.